129 related articles for article (PubMed ID: 7563939)
1. [Successful treatment of a 74-year-old man with refractory anemia with excess of blasts in transformation (RAEB in T) by low-dose Ara-C injection].
Wataya S; Sudou H; Sakamaki I; Wano Y; Ueda T; Nakamura T
Nihon Ronen Igakkai Zasshi; 1995 Jun; 32(6):438-41. PubMed ID: 7563939
[TBL] [Abstract][Full Text] [Related]
2. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
3. Small-dose cytosine arabinoside in the treatment of elderly patients with acute leukemia and refractory anemia with excess of blast.
Satou Y; Kubota T; Yonekura S; Noguchi K; Oobayashi Y; Nagao T; Arimori S
Tokai J Exp Clin Med; 1986 Oct; 11(4):249-54. PubMed ID: 3617109
[TBL] [Abstract][Full Text] [Related]
4. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
[TBL] [Abstract][Full Text] [Related]
5. [Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate].
Takeuchi M; Kojima K; Takaba S; Isokawa M; Tanimizu M; Kimura F; Ohmoto E; Harada M
Gan To Kagaku Ryoho; 1995 Jan; 22(1):141-4. PubMed ID: 7826071
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
7. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
[TBL] [Abstract][Full Text] [Related]
8. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
9. Low dose cytosine arabinoside in refractory anemia with excess of blasts in transformation.
Fridrik MA; Wahl G; Herbinger W
Blut; 1988 Dec; 57(6):357-60. PubMed ID: 3207893
[TBL] [Abstract][Full Text] [Related]
10. [Effects of low dose Ara-C regimen in acute leukemias and RAEB].
Kohno T; Nagai K; Tsukazaki K; Jinnai I; Tomonaga M; Ichimaru M; Tagawa M
Rinsho Ketsueki; 1989 May; 30(5):638-43. PubMed ID: 2795877
[TBL] [Abstract][Full Text] [Related]
11. Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; de Witte T; Jacobs A; Visiani G; Fiere D; Sonneveld P; Labar B
Infection; 1992; 20 Suppl 2():S116-23. PubMed ID: 1493935
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.
Fenaux P; Morel P; Rose C; Lai JL; Jouet JP; Bauters F
Br J Haematol; 1991 Apr; 77(4):497-501. PubMed ID: 2025575
[TBL] [Abstract][Full Text] [Related]
13. Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Corsetti MT; Salvi F; Perticone S; Baraldi A; De Paoli L; Gatto S; Pietrasanta D; Pini M; Primon V; Zallio F; Tonso A; Alvaro MG; Ciravegna G; Levis A
Leuk Res; 2011 Aug; 35(8):991-7. PubMed ID: 21474179
[TBL] [Abstract][Full Text] [Related]
14. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
Katayama N; Tanaka I; Minami N; Shirakawa S
Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
[TBL] [Abstract][Full Text] [Related]
15. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
Omine M; Yamauchi H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
Miyazaki Y; Kiguchi T; Sato S; Usuki K; Ishiyama K; Ito Y; Suzuki T; Taguchi J; Chiba S; Dobashi N; Tomita A; Harada H; Handa H; Horiike S; Maeda T; Matsuda M; Ichikawa M; Hata T; Honda S; Iyama S; Suzushima H; Moriuchi Y; Kurokawa T; Yokota K; Ohtake S; Yamauchi T; Matsumura I; Kiyoi H; Naoe T;
Int J Hematol; 2022 Aug; 116(2):228-238. PubMed ID: 35508695
[TBL] [Abstract][Full Text] [Related]
17. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndromes in childhood. Report of 21 patients from Italy and West Germany.
Creutzig U; Cantù-Rajnoldi A; Ritter J; Romitti L; Odenwald E; Conter V; Riehm H; Masera G
Am J Pediatr Hematol Oncol; 1987; 9(4):324-30. PubMed ID: 3439582
[TBL] [Abstract][Full Text] [Related]
19. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes.
Gyger M; Infante-Rivard C; D'Angelo G; Forest L; Lussier P
Am J Hematol; 1988 May; 28(1):13-20. PubMed ID: 3369432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
